Drugs / teprasiran
teprasiran
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00683553 | May 2008 → May 2010 | acute kidney injury | Quark Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00554359 | Aug 2007 → Oct 2010 | acute kidney injury | Quark Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00802347 | Dec 2008 → Nov 2013 | disease related to solid organ transplantation | Quark Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT02610283 Comparator | Dec 2015 → Feb 2018 | acute kidney injury | Quark Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03510897 Comparator | Jun 2018 → Oct 2020 | cardiac valvular defect | Quark Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02610296 Comparator | Mar 2016 → Jun 2018 | — | Quark Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-07-27 | Silence Therapeutics GmbH | Results Licensee Quark Pharmaceuticals announces positive Phase 2 data in Acute Kidney Injury silence-therapeutics.com ↗
Quark reported that the trial’s primary endpoint and multiple secondary endpoints were met. |
| 2014-07-30 | Silence Therapeutics GmbH | Results Licensee Confirms Favourable Trial Outcome silence-therapeutics.com ↗
Silence Therapeutics plc, AIM: SLN (‘Silence’ or ‘the Company’), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, announces that licence holder Quark Pharmaceuticals, Inc. (‘Quark’) has confirmed favourable results in its Phase 2 trial for the use of QPI-1002 short interfering RNA (siRNA) for the prevention of delayed graft function (DGF) in kidney transplant patients (QRK.006B; ClinicalTrials.gov identifier: NCT00802347). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-07-27 | Silence Therapeutics GmbH | Licensee Quark Pharmaceuticals announces positive Phase 2 data in Acute Kidney Injury silence-therapeutics.com ↗ |
| 2014-07-30 | Silence Therapeutics GmbH | Licensee Confirms Favourable Trial Outcome silence-therapeutics.com ↗ |
| 2010-08-19 | Silence Therapeutics GmbH | Quark Signs Exclusive Option Agreement with Novartis for QPI-1002 silence-therapeutics.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | teprasiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03510897 ↗ |
| Known as | I5NP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00554359 ↗ |
| Known as | QPI-1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02610296 ↗ |
| Action | Inhibit | “temporarily inhibits p53-mediated cell death” PMID 34474590 ↗ Sep 2021 |
| Modality | Small interfering RNA (siRNA) | “The drug (I5NP) is a small interfering RNA” NCT00554359 ↗ |
| Route | Intravenous | “Patients will receive a single IV injection of I5NP or placebo following cardiovascular surgery.” NCT00554359 ↗ |